Posts Tagged ‘best cancer research’

Study shows soy is not only safe for breast cancer survivors, it may also be beneficial

March 5, 2010

Cleveland Plain Dealer – Despite soy’s healthy profile, many women who have had breast cancer are reluctant to eat soy foods. And many cancer doctors caution their patients against doing so.

The concern stems from substances in soy called isoflavones, which behave like weak estrogen in the body. Estrogen, a hormone that controls the menstrual cycle, has been shown to increase the risk of breast cancer in women.

Here’s how: Estrogen stimulates cells to divide. Cancer arises from DNA mutations in cells — errors that occasionally happen during cell division. If one of these spontaneous mutations occurs in a gene that controls cell growth and division, it could lead to the development of cancer.

Another worry is the interaction between isoflavones and tamoxifen, a breast cancer drug that blocks estrogen from cells.

But a study published in the December issue of the Journal of the American Medical Association may set those fears aside.

The study, by researchers at Vanderbilt University, says soy foods are safe — and possibly beneficial — for breast cancer survivors. They looked at 5,042 women in China who were breast cancer survivors and divided them into four groups based on how much soy they ate. Women who ate low amounts of soy consumed an average of about a half-cup of soy milk a day, while the high-soy-consumption group had about three cups a day.

After four years, 10.3 percent of those who consumed the least soy died, compared with 7.4 percent of those who had the most, leading researchers to theorize that soy did not increase breast cancer occurrence and may have had some protective effect.

CWRUmedicine’s breast cancer specialist, Dr. Paula Silverman, often gets questions from her patients about whether it’s safe to eat soy. Her answer: Go ahead and enjoy.

“I don’t think there was good data about that, ever,” says Silverman, medical director of the Breast Cancer Program at University Hospitals Case Medical Center. “I’ve always felt that soy was probably safe.” Some years ago, Silverman heard a lecture by a physician who made a compelling argument that plant estrogens and human estrogens are not the same. Silverman thinks the weak estrogens in soy may act more like tamoxifen than like human estrogen. “The bottom line is dietary soy is safe for breast cancer survivors,” Silverman says.

The National Institutes of Health says it remains unclear what role dietary soy or soy isoflavone might play in cancer risk. While several large population studies have reported that higher soy intake is associated with a decreased risk of developing various types of cancers, including breast, prostate and colon cancer, other research suggests soy does not have this effect.

Read the Full Story on

WVIZ PBS Ideastream talk with CWRUmedicine faculty about “confronting colon cancer”

March 2, 2010

According to the American Cancer Society, colon cancer is the second-leading cause of cancer-related deaths in the United States. Tonight at 7:30 p.m. on WVIZ/PBS Ideastream, several CWRUmedicine’s Hematology Oncology specialists are featured in “Confronting Colon Cancer” – an in-depth look at the disease from detection and diagnosis through treatment. Tune in tonight or watch the special online below.

To learn more about cancer research, visit

DNA Screening for Colon Cancer Video

February 26, 2010

It is estimated that colon cancer will kill 50,000 people in the United States this year. But found early, that number could be lowered substantially. So why do so many still die from it? The answer and the solution can be found in a medical laboratory in Cleveland, Ohio.

A team of researchers led by Sanford Markowitz, M.D., Ph.D. at the Case Western Reserve University Department of Medicine has found a way to detect colon cancer quickly and non-invasively.
Learn more at

Hem Onc clinical trials

February 24, 2010

Matthew Cooney, MD, discusses the importance of clinical trials in cancer treatments.
Learn more about the Division of Hematoloy Oncology ::

The importance of Hem Onc clinical trials

February 24, 2010

Matthew Cooney, MD, discusses the importance of clinical trials in cancer treatments.
Learn more about the Division of Hematoloy Oncology ::

HemOnc approach to cancer

February 24, 2010

Matthew Cooney, MD, discusses the multidisciplinary approach to cancer treatment at the Department of Medicine at Case Western Reserve University.
Learn more about the Division of Hematoloy Oncology ::

CWRUmedicine’s HemOnc researchers publish new findings that may lead to a new standard of care for patients with locally advanced cervical cancer

February 24, 2010

Published in the February 2010 issue of Clinical Cancer Research, the phase one study found that a new chemotherapy medicine, Triapine, was well tolerated in combination with standard-of-care cisplatin chemotherapy and radiation treatment in women with cervical cancer. This regimen provided both significant reduction in cancer disease and cancer control.

“This new drug, which suppresses tumor growth, shows a great deal of promise for cervical cancer patients who are at high risk for relapse and cancer-related death,” says Charles Kunos, MD, Primary Investigator of the study, Director of Gynecologic Radiation Oncology at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine. “In this ten-patient study, a 100% complete response rate was observed and no disease progression was documented through 18 months of median follow-up.”

In the study, patients were treated three times weekly with Triapine in combination with weekly cisplatin treatment and daily pelvic radiation therapy over five weeks. A phase two follow-up study is ongoing at the Ireland Cancer Center. UH Case Medical Center is the primary affiliate of Case Western Reserve University School of Medicine, a nationally recognized leader in medical research and education.

“Cervical cancer affects half a million women worldwide each year,” says Steven Waggoner, MD, Chief of Gynecologic Oncology at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine. “We are pleased to have found a promising new treatment to help women fight this aggressive disease.”

Source :: NewsRx